Frequent and unpredictable changes in COVID-19 policies and restrictions reduce the accuracy of model forecasts.
Houdroge F, Palmer A, Delport D, Walsh T, Kelly SL, Hainsworth SW, Abeysuriya R, Stuart RM, Kerr CC, Coplan P, Wilson DP, Scott N
COVID-19
Cost optimisation analysis of the expanded programme for immunisation: balancing equity and coverage in Pakistan.
Houdroge F, Yunus H, Delport D, Stearns E, Palmer A, Naim A, Kashif A, Pyne HH, Scott N, Oelrichs R, Wilson D
Immunisation + Health Systems Strengthening
Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study.
Scott DN, Palmer MA, Tidhar MT, Stoove PM, Sacks-Davis DRS, Doyle AJS, Pedrana DAJ, Thompson PA, Wilson PDP, Hellard PM
A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
Palmer AY, Chan K, Gold J, Layton C, Elsum I, Hellard M, Stoove M, Doyle JS, Pedrana A, Scott N, on the EC Partnership
Covasim: An agent-based model of COVID-19 dynamics and interventions.
Kerr CC, Stuart RM, Mistry D, Abeysuriya RG, Rosenfeld K, Hart GR, Núñez RC, Cohen JA, Selvaraj P, Hagedorn B, George L, Jastrzębski M, Izzo AS, Fowler G, Palmer A, Delport D, Scott N, Kelly SL, Bennette CS, Wagner BG, Chang ST, Oron AP, Wenger EA, Panovska-Griffiths J, Famulare M, Klein DJ
COVID-19
Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scale-up of direct-acting antiviral treatment.
Palmer AY, Wilkinson A, Aitken C, Dietze P, Dore GJ, Maher L, Sacks-Davis R, Stoove M, Wilson D, Hellard M, Scott N